Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine

Vaccine

Volumn 33, Issue 5, 2015, Pages 686-692

  Torres, Alfredo G ^a   Gregory, Anthony E ^b   Hatcher, Christopher L ^a   Vinet Oliphant, Heather ^c   Morici, Lisa A ^d   Titball, Richard W ^b   Roy, Chad J ^c,d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol; Burkholderia mallei; Glanders; Glycoconjugate; Macaques; Nanoparticles

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; GLYCOCONJUGATE; GOLD NANOPARTICLE; IMMUNOGLOBULIN G; PROTEIN DERIVATIVE; PROTEIN FLIC; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; GOLD; LIPOPOLYSACCHARIDE; NANOPARTICLE; VACCINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM ISOLATION; BURKHOLDERIA MALLEI; BURKHOLDERIA THAILANDENSIS; CONTROLLED STUDY; DRUG EFFICACY; GLANDERS; IMMUNOGLOBULIN BLOOD LEVEL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SURVIVAL; VACCINATION; ANIMAL; BLOOD; DISEASE MODEL; IMMUNOLOGY; SURVIVAL ANALYSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BURKHOLDERIA MALLEI; DISEASE MODELS, ANIMAL; GLANDERS; GLYCOCONJUGATES; GOLD; LIPOPOLYSACCHARIDES; MACACA MULATTA; NANOPARTICLES; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 84921293412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.057     Document Type: Article

References (20)

1. Whitlock G.C., Estes D.M., Torres A.G. Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett 2007, 277:115-122.
2. Galyov E.E., Brett P.J., Deshazer D. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol 2010, 64:495-517.
3. Wheelis M. First shots fired in biological warfare. Nature 1998, 395:213.
4. Van Zandt K.E., Greer M.T., Gelhaus H.C. Glanders: an overview of infection in humans. Orphanet J Rare Dis 2013, 8:131.
5. Lipsitz R., Garges S., Aurigemma R., Baccam P., Blaney D.D., Cheng A.C., et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis 2012, 18:e2.
6. Silva E.B., Dow S.W. Development of Burkholderia mallei and pseudomallei vaccines. Front Cell Infect Microbiol 2013, 3:10.
7. Burtnick M.N., Heiss C., Roberts R.A., Schweizer H.P., Azadi P., Brett P.J. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol 2012, 2:108.
8. Qazi O., Prior J.L., Judy B.M., Whitlock G.C., Kitto G.B., Torres A.G., et al. Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Trans R Soc Trop Med Hyg 2008, 102:S58-S60.
9. Nelson M., Prior J.L., Lever M.S., Jones H.E., Atkins T.P., Titball R.W., et al. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 2004, 53:1177-1182.
10. Brett P.J., Woods D.E. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect Immun 1996, 64:2824-2828.
11. Krishnamachari Y., Geary S.M., Lemke C.D., Salem A.K. Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011, 28:215-236.
12. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
13. Shah M., Badwaik V.D., Dakshinamurthy R. Biological applications of gold nanoparticles. J Nanosci Nanotechnol 2014, 14:344-362.
14. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particlemediated DNA vaccines for infectious diseases. Methods 2006, 40:86-97.
15. Gregory A.E., Judy B.M., Qazi O., Blumentritt C.A., Brown K.A., Shaw A.M., et al. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 2014, Sep 3 [Epub ahead of print].
16. Hartings J.M., Roy C.J. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J Pharmacol Toxicol Methods 2004, 49:39-55.
17. West T.E., Ernst R.K., Jansson-Hutson M.J., Skerrett S.J. Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol 2008, 9:46.
18. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4:1247-1253.
19. Sprague L.D., Zysk G., Hagen R.M., Meyer H., Ellis J., Anuntagool N., et al. A possible pitfall in the identification of Burkholderia mallei using molecular identification systems based on the sequence of the flagellin fliC gene. FEMS Immunol Med Microbiol 2002, 34:231-236.
20. Bergman M.A., Cummings L.A., Alaniz R.C., Mayeda L., Fellnerova I., Cookson B.T. CD4+ T-cell responses generated during murine Salmonella enterica serovar Typhimurium infection are directed towards multiple epitopes within the natural antigen FliC. Infect Immun 2005, 73:7226-7235.